Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib in Relapsed/Refractory CLL
NCT04204057Phase 2Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Nov 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tenalisib in chronic lymphocytic leukemia (CLL), sponsored by Rhizen Pharmaceuticals AG. Started Nov 2019; status: completed.
02
Drugs
tenalisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04204057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204057.